| Business Summary | | Halsey
Drug
Company,
Inc.
and
its
subsidiaries
are
engaged
in
the
development,
manufacture,
sale,
and
distribution
of
generic
drugs
and
active
pharmaceutical
ingredients
(APIs).
Through
its
strategic
alliance
with
Watson
Pharmaceuticals,
the
Company
sells
its
generic
drug
products
under
the
Watson
name
for
distribution
by
Watson
to
drugstore
chains
and
drug
wholesalers.
APIs,
also
known
as
bulk
chemical
products,
are
used
in
the
development
and
manufacture
of
finished
dosage
pharmaceutical
products.
The
development
and
sale
of
APIs
generally
is
not
subject
to
the
same
level
of
regulation
as
is
the
development
and
sale
of
finished
dosage
products.
As
a
result,
APIs
may
be
brought
to
market
substantially
sooner
than
finished
dosage
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Halsey
Drug
Company
is
engaged
in
the
manufacture,
sale
and
distribution
of
generic
drugs.
The
Company
has
manufactured
and
sold
a
broad
range
of
prescription
and
over-the-counter
drug
products.
For
the
three
months
ended
3/31/01
revenues
totalled
$8
million
up
from
$3.2
million.
Net
loss
fell
97%
to
$106
thousand.
Results
reflect
the
sale
of
certain
product
rights
to
Watson
Pharmaceuticals,
Inc.
Lower
loss
also
reflects
increased
gross
margins. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
1,962;
after
tax
earnings
were
-4,596. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Michael Reicher, 54 Chairman,
CEO | $175K | Gerald Price, 53 Pres,
COO, Director | 50K | James Emigh, 45 VP-Operations | 125K | Peter Clemens, 48 VP,
CFO | 140K | Phyllis Lambridis, 39 VP
of corporate compliance | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|